Biocracked
Approach: Macro science, the human outcome angle through tissue. Palette: D, bold color field.

Extreme close-up of a cross-section of raw beef thigh muscle, used as a stand-in for human thigh tissue. It is shot straight on and slightly from above, on a saturated tomato-red seamless backdrop. Fine white fat marbling threads run through the dark red muscle fibers. On one half the marbling is dense and lacy, and on the other it is sparse and clean, so the contrast reads as a before and after. A thin, translucent calipers-style steel ruler lies along the edge, with no markings readable. Lighting is soft, directional studio light from the upper left, with crisp highlights on the glistening fibers and gentle warm shadows. A single small electric green surgical marker dot sits on the tissue. The mood is analytical, tense and uncertain, with shallow depth of field and sharp detail on the fat texture.
Longevity

High-Dose Semaglutide and Thigh Muscle: What the MRI Shows

Helix Ward · · 5 min read

Few worries about GLP-1 drugs spread as quickly as the fear of losing muscle along with fat. A new MRI sub-analysis of the STEP UP trial, which tested semaglutide at 7.2 mg (well above the 2.4 mg Wegovy dose), offers a more nuanced picture than either the alarmists or the optimists would like. It is also a small study, and it needs careful reading.

What the study did

STEP UP was a phase 3b trial that randomised adults with a BMI of 30 or higher to weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo for 72 weeks, alongside a lifestyle intervention. This prespecified secondary analysis, published in Diabetes, Obesity and Metabolism and led by Jøran Hjelmesæth, looked at MRI-measured body composition and a physical function test.

Here is the catch: only 55 of the 1,407 trial participants had a valid baseline scan and were included. Of those, 43 took semaglutide 7.2 mg, 6 took 2.4 mg, and just 6 received placebo. The researchers pooled the two semaglutide arms (n = 49) and compared them with placebo.

The headline findings

Compared with placebo, the pooled semaglutide group showed:

  • Total adipose tissue: down 11.1 L (95% CI -16.5 to -5.7; p < 0.0001)
  • Visceral adipose tissue: down 1.5 L (p = 0.04)
  • Lean body tissue: down 1.7 L (95% CI -4.0 to 0.7; p = 0.16)
  • Thigh skeletal muscle volume: down 1.1 L (95% CI -2.3 to 0.1; p = 0.07)
  • Thigh muscle fat infiltration: down 0.92 percentage points (p = 0.001)

A sensitivity analysis comparing only the 7.2 mg group with placebo produced similar results. Relative changes also pointed the same way.

Fat loss is clear, muscle volume is not

The fat result is robust, even with a small sample. Losing about 11 liters of adipose tissue relative to placebo, including a measurable drop in visceral fat, is what you would expect from a drug at this dose.

The muscle result is harder to interpret. The thigh muscle volume change did not reach statistical significance, but the p-value of 0.07 and a confidence interval running from -2.3 L to +0.1 L do not amount to evidence of no loss. With only six placebo participants, the study had very little power to detect a difference. "Not significant" here mostly means "we can't tell." The authors' own conclusion says semaglutide was associated with reductions in adipose tissue, skeletal muscle volume and muscle fat infiltration, so they do not claim muscle was spared.

In raw liters, the thigh muscle change was roughly a tenth of the fat change. That comparison should be treated loosely, since these are different tissues and compartments, but it fits what larger body-composition studies of weight-loss drugs have generally suggested: most of the lost mass is fat, with a meaningful minority from lean tissue. Lean tissue also includes water, organs and other non-muscle components, so a drop in lean mass is not automatically a drop in muscle.

The muscle quality signal

The more interesting result is the fall in thigh muscle fat infiltration. Fat deposited within and between muscle fibers is associated with poorer strength and metabolic health, and it tends to accumulate with obesity, insulin resistance and aging. A 0.92 percentage point reduction suggests the muscle that remained was somewhat "cleaner."

Temper the enthusiasm, though. The absolute change is small, and the study did not show that it translates into better strength, mobility or long-term outcomes. Fat infiltration is a proxy marker, not a functional result.

Physical function: reassuring but limited

The functional measure was a 30-second sit-to-stand test. The abstract reports a mean of about 13 repetitions at baseline and 15 at week 72 across the pooled semaglutide and placebo groups. Function did not worsen, which is encouraging. But the test is a coarse measure, it was done in a small subset, and the abstract does not give a clean treatment-versus-placebo contrast. It is not a substitute for strength testing such as grip strength or leg press.

Important caveats

  • Tiny comparison group: Six placebo participants make every between-group estimate fragile.
  • Subset selection: Participants with valid baseline MRI scans may not represent the full trial population.
  • Industry involvement: The trial was a Novo Nordisk study, and several authors are Novo Nordisk employees or shareholders. The MRI analysis involved AMRA Medical, whose authors also disclosed industry ties. This does not invalidate the data, but it is context readers should weigh.
  • Secondary analysis: Findings are hypothesis-generating, not definitive.
  • Lifestyle component: Participants received lifestyle intervention, so results may not apply to someone taking the drug without support.

The authors themselves call for further research on how weight loss affects muscle composition and function.

Practical takeaways for people on GLP-1s

The study cannot tell you how to protect muscle, since it did not test any muscle-sparing strategy. But it does reinforce a sensible approach based on broader evidence in weight loss and aging:

  1. Lift weights. Resistance training two to three times a week is the most reliable signal telling your body to keep muscle during a calorie deficit.
  2. Prioritise protein. Reduced appetite can quietly push protein intake too low. Many clinicians suggest aiming for roughly 1.2 to 1.6 g per kg of body weight daily, adjusted for kidney health and individual needs. Check with your care team.
  3. Don't rely on the scale. Track waist circumference, strength, and how easily you do daily tasks. If possible, use body composition measurements as well.
  4. Be careful if you're older or already frail. Those at risk of sarcopenia have less margin for muscle loss and may benefit from closer monitoring.
  5. Ask about dose and pacing. Faster, larger weight loss means more total tissue loss, which makes protection strategies more important.

The bottom line

This small MRI analysis suggests that high-dose semaglutide mostly removes fat, including visceral fat, while thigh muscle fat infiltration improves and basic physical function holds up. It does not prove muscle is safe. The thigh muscle volume estimate leans toward a loss, and the sample is too small to settle the question. For anyone on a GLP-1 drug, the message is not to panic about muscle, but not to ignore it either. Fat loss can come with a bonus, and the muscle you keep is largely something you have to train and feed.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

HW

Written by

Helix Ward

Helix Ward writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
peptides

Semaglutide Didn't Shrink Human Muscle Cells. So Why the Muscle Loss?

BY DR. SYNAPSE ·

Does semaglutide really eat your muscle? A new GeroScience study put the drug straight onto primary human muscle cells from older adults with obesity, and the cells didn't waste. No atrophy genes switched on, no secretome alarms, and GIP even thickened myotubes after eight days. Semaglutide did modestly dial down glycolytic ATP production, and GLP-1 receptors were barely detectable. The findings point toward indirect causes of lean mass loss, like calorie deficit and reduced loading, though a dish is not a body.

Approach: 3, the human outcome, here as an animal-science moment. Palette: C, natural.

An old female lab mouse with slightly greying, ruffled fur sits upright on a researcher's open gloved palm, photographed at eye level in a close side-on view with a shallow depth of field. Behind it, a softly blurred animal facility window pours in real morning daylight, giving the scene a pale green-grey and warm-wood setting. The nitrile glove is a vivid electric green (#00e676), the single saturated accent. The mouse's whiskers and pink ears catch the light, and the researcher's white coat sleeve is just visible. Tones are natural: skin, soft cream bedding, sage walls. The mood is calm, careful and quietly hopeful, and it conveys age and care rather than drama. The image has no text, no labels and no readable writing.
longevity

Ozempic's Active Ingredient Extended Lifespan in Old Mice. Here's Why

BY DR. SYNAPSE ·

Semaglutide, the active ingredient in Ozempic and Wegovy, extended lifespan in old female mice in a new Nature study from UC Berkeley. Treatment began at 20 months of age and mimicked many benefits of calorie restriction. In a direct comparison, the drug also showed more favourable trajectories than matched calorie restriction in exploratory drive, spatial memory and glucose control. But this is mouse research in females only, with no dosing guidance for humans. Here is what the findings suggest, and what they do not.

Approach: the human outcome. Palette: natural.

A close, slightly low-angle shot of an elderly person's weathered hands resting on a wooden kitchen table beside a tall glass of creamy shake, a steel spoon and a small bowl of white creatine powder. Their forearm is relaxed, with visible tendons, age spots and loose skin, and the fingers are curled lightly as if gripping would take effort. Soft morning daylight comes through a window on the left, giving warm skin tones, a honey-colored oak table and blurred green houseplant leaves in the background. A thin ribbon of electric green from a straw or a cloth napkin gives a single small accent. The shallow depth of field keeps the face out of frame. The mood is quiet, dignified and hopeful but restrained, with no gym, no dumbbells and no text.
longevity

Creatine-Leucine-MCT Stack Added Muscle in 77-Year-Olds, Not Strength

BY DR. SYNAPSE ·

A randomized trial in 73 sarcopenic adults averaging 77 found that an eight-week supplement built on creatine, leucine-rich protein and MCT raised appendicular muscle mass by 0.42 kg (+3.2%) without any exercise. The gain was statistically significant against placebo but fell below the minimal clinically important difference. Handgrip strength did not differ between groups, even though placebo participants lost about 7% of their grip. The formula also included whey, resveratrol and vitamin D3, so no single ingredient can take the credit. For older adults who cannot train, it looks like a safe adjunct, but not a replacement for resistance exercise.

**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
metabolism

Do Ozempic and Mounjaro Cause Depression? What 20 Studies Found

BY DR. SYNAPSE ·

Do Ozempic and Mounjaro cause depression or suicidal thoughts? A new systematic review of 20 studies plus EMA and FDA assessments says the best evidence doesn't show it. Randomized data, including two large 2025 meta-analyses, found no increased suicidality, depression, or anxiety with semaglutide or tirzepatide. The scarier signals came from study designs that can't separate drug effects from obesity-related distress, baseline psychiatric risk, and reporting bias. But trials excluded many psychiatric patients, so surveillance still matters for high-risk groups and rare long-term outcomes.

This page is available in